Emerging role of the immunotherapy in treatment of breast cancer

Background: Breast cancer is a life-threatening malignant tumor that ranks the most frequent cancerin females worldwide. Emerging studies suggest the important role of the immunotherapy in breast cancer.Triple negative breast cancer (TNBC) is associated with the worst prognosis and is resistantto th...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Nagwa Abd El-Sadek Ahmed* [verfasserIn] Maisa Hashem Mohammed [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2021

Schlagwörter:	tnbc; immunotherapy; programmed death 1; programmed death ligand 1

Übergeordnetes Werk:	In: SVU - International Journal of Medical Sciences - South Valley University, Faculty of Medicine, 2021, 4(2021), 2, Seite 172-176
Übergeordnetes Werk:	volume:4 ; year:2021 ; number:2 ; pages:172-176

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

Katalog-ID:	DOAJ048933864

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ048933864
003	DE-627
005	20230502074105.0
007	cr uuu---uuuuu
008	230227s2021 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)DOAJ048933864
035			\|a (DE-599)DOAJ26388b06d23f4792a6393dbf70d5ba4f
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	0		\|a Nagwa Abd El-Sadek Ahmed* \|e verfasserin \|4 aut
245	1	0	\|a Emerging role of the immunotherapy in treatment of breast cancer
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Background: Breast cancer is a life-threatening malignant tumor that ranks the most frequent cancerin females worldwide. Emerging studies suggest the important role of the immunotherapy in breast cancer.Triple negative breast cancer (TNBC) is associated with the worst prognosis and is resistantto the conventional therapeutic agents. Recently, the immunotherapy has achieved satisfactory results in the treatment of breast cancer in general and in TNBC in particular. The immune checkpoints are targeted in many clinical trials. The checkpoint inhibitors results in advances in treatment of breast cancer, especially refractory molecular subtypes. This review is aimedto highlight the current knowledge on the immunotherapy and the advances in its implications in treatment of breast cancer with emphasis on newly approved therapeutic approaches in this field. Conclusion: The immunotherapy is considered as an emerging therapeutic strategy for treatment of breast cancer, particularly TNBC.Several clinical trials focusing on the potential role of immunotherapy in breast cancer are still under research.
650		4	\|a tnbc; immunotherapy; programmed death 1; programmed death ligand 1
653		0	\|a Medicine
653		0	\|a R
700	0		\|a Maisa Hashem Mohammed \|e verfasserin \|4 aut
773	0	8	\|i In \|t SVU - International Journal of Medical Sciences \|d South Valley University, Faculty of Medicine, 2021 \|g 4(2021), 2, Seite 172-176 \|w (DE-627)1761094386 \|x 26363402 \|7 nnns
773	1	8	\|g volume:4 \|g year:2021 \|g number:2 \|g pages:172-176
856	4	0	\|u https://dx.doi.org/10.21608/svuijm.2020.47814.1018 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/26388b06d23f4792a6393dbf70d5ba4f \|z kostenfrei
856	4	0	\|u https://svuijm.journals.ekb.eg/article_122698.html \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2735-427X \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2636-3402 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 4 \|j 2021 \|e 2 \|h 172-176

Indexfelder

author_variant	n a e s a naesa m h m mhm
matchkey_str	article:26363402:2021----::mrigoefhimnteaynram
hierarchy_sort_str	2021
publishDate	2021
allfields	(DE-627)DOAJ048933864 (DE-599)DOAJ26388b06d23f4792a6393dbf70d5ba4f DE-627 ger DE-627 rakwb eng Nagwa Abd El-Sadek Ahmed* verfasserin aut Emerging role of the immunotherapy in treatment of breast cancer 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Breast cancer is a life-threatening malignant tumor that ranks the most frequent cancerin females worldwide. Emerging studies suggest the important role of the immunotherapy in breast cancer.Triple negative breast cancer (TNBC) is associated with the worst prognosis and is resistantto the conventional therapeutic agents. Recently, the immunotherapy has achieved satisfactory results in the treatment of breast cancer in general and in TNBC in particular. The immune checkpoints are targeted in many clinical trials. The checkpoint inhibitors results in advances in treatment of breast cancer, especially refractory molecular subtypes. This review is aimedto highlight the current knowledge on the immunotherapy and the advances in its implications in treatment of breast cancer with emphasis on newly approved therapeutic approaches in this field. Conclusion: The immunotherapy is considered as an emerging therapeutic strategy for treatment of breast cancer, particularly TNBC.Several clinical trials focusing on the potential role of immunotherapy in breast cancer are still under research. tnbc; immunotherapy; programmed death 1; programmed death ligand 1 Medicine R Maisa Hashem Mohammed verfasserin aut In SVU - International Journal of Medical Sciences South Valley University, Faculty of Medicine, 2021 4(2021), 2, Seite 172-176 (DE-627)1761094386 26363402 nnns volume:4 year:2021 number:2 pages:172-176 https://dx.doi.org/10.21608/svuijm.2020.47814.1018 kostenfrei https://doaj.org/article/26388b06d23f4792a6393dbf70d5ba4f kostenfrei https://svuijm.journals.ekb.eg/article_122698.html kostenfrei https://doaj.org/toc/2735-427X Journal toc kostenfrei https://doaj.org/toc/2636-3402 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2021 2 172-176
spelling	(DE-627)DOAJ048933864 (DE-599)DOAJ26388b06d23f4792a6393dbf70d5ba4f DE-627 ger DE-627 rakwb eng Nagwa Abd El-Sadek Ahmed* verfasserin aut Emerging role of the immunotherapy in treatment of breast cancer 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Breast cancer is a life-threatening malignant tumor that ranks the most frequent cancerin females worldwide. Emerging studies suggest the important role of the immunotherapy in breast cancer.Triple negative breast cancer (TNBC) is associated with the worst prognosis and is resistantto the conventional therapeutic agents. Recently, the immunotherapy has achieved satisfactory results in the treatment of breast cancer in general and in TNBC in particular. The immune checkpoints are targeted in many clinical trials. The checkpoint inhibitors results in advances in treatment of breast cancer, especially refractory molecular subtypes. This review is aimedto highlight the current knowledge on the immunotherapy and the advances in its implications in treatment of breast cancer with emphasis on newly approved therapeutic approaches in this field. Conclusion: The immunotherapy is considered as an emerging therapeutic strategy for treatment of breast cancer, particularly TNBC.Several clinical trials focusing on the potential role of immunotherapy in breast cancer are still under research. tnbc; immunotherapy; programmed death 1; programmed death ligand 1 Medicine R Maisa Hashem Mohammed verfasserin aut In SVU - International Journal of Medical Sciences South Valley University, Faculty of Medicine, 2021 4(2021), 2, Seite 172-176 (DE-627)1761094386 26363402 nnns volume:4 year:2021 number:2 pages:172-176 https://dx.doi.org/10.21608/svuijm.2020.47814.1018 kostenfrei https://doaj.org/article/26388b06d23f4792a6393dbf70d5ba4f kostenfrei https://svuijm.journals.ekb.eg/article_122698.html kostenfrei https://doaj.org/toc/2735-427X Journal toc kostenfrei https://doaj.org/toc/2636-3402 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2021 2 172-176
allfields_unstemmed	(DE-627)DOAJ048933864 (DE-599)DOAJ26388b06d23f4792a6393dbf70d5ba4f DE-627 ger DE-627 rakwb eng Nagwa Abd El-Sadek Ahmed* verfasserin aut Emerging role of the immunotherapy in treatment of breast cancer 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Breast cancer is a life-threatening malignant tumor that ranks the most frequent cancerin females worldwide. Emerging studies suggest the important role of the immunotherapy in breast cancer.Triple negative breast cancer (TNBC) is associated with the worst prognosis and is resistantto the conventional therapeutic agents. Recently, the immunotherapy has achieved satisfactory results in the treatment of breast cancer in general and in TNBC in particular. The immune checkpoints are targeted in many clinical trials. The checkpoint inhibitors results in advances in treatment of breast cancer, especially refractory molecular subtypes. This review is aimedto highlight the current knowledge on the immunotherapy and the advances in its implications in treatment of breast cancer with emphasis on newly approved therapeutic approaches in this field. Conclusion: The immunotherapy is considered as an emerging therapeutic strategy for treatment of breast cancer, particularly TNBC.Several clinical trials focusing on the potential role of immunotherapy in breast cancer are still under research. tnbc; immunotherapy; programmed death 1; programmed death ligand 1 Medicine R Maisa Hashem Mohammed verfasserin aut In SVU - International Journal of Medical Sciences South Valley University, Faculty of Medicine, 2021 4(2021), 2, Seite 172-176 (DE-627)1761094386 26363402 nnns volume:4 year:2021 number:2 pages:172-176 https://dx.doi.org/10.21608/svuijm.2020.47814.1018 kostenfrei https://doaj.org/article/26388b06d23f4792a6393dbf70d5ba4f kostenfrei https://svuijm.journals.ekb.eg/article_122698.html kostenfrei https://doaj.org/toc/2735-427X Journal toc kostenfrei https://doaj.org/toc/2636-3402 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2021 2 172-176
allfieldsGer	(DE-627)DOAJ048933864 (DE-599)DOAJ26388b06d23f4792a6393dbf70d5ba4f DE-627 ger DE-627 rakwb eng Nagwa Abd El-Sadek Ahmed* verfasserin aut Emerging role of the immunotherapy in treatment of breast cancer 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Breast cancer is a life-threatening malignant tumor that ranks the most frequent cancerin females worldwide. Emerging studies suggest the important role of the immunotherapy in breast cancer.Triple negative breast cancer (TNBC) is associated with the worst prognosis and is resistantto the conventional therapeutic agents. Recently, the immunotherapy has achieved satisfactory results in the treatment of breast cancer in general and in TNBC in particular. The immune checkpoints are targeted in many clinical trials. The checkpoint inhibitors results in advances in treatment of breast cancer, especially refractory molecular subtypes. This review is aimedto highlight the current knowledge on the immunotherapy and the advances in its implications in treatment of breast cancer with emphasis on newly approved therapeutic approaches in this field. Conclusion: The immunotherapy is considered as an emerging therapeutic strategy for treatment of breast cancer, particularly TNBC.Several clinical trials focusing on the potential role of immunotherapy in breast cancer are still under research. tnbc; immunotherapy; programmed death 1; programmed death ligand 1 Medicine R Maisa Hashem Mohammed verfasserin aut In SVU - International Journal of Medical Sciences South Valley University, Faculty of Medicine, 2021 4(2021), 2, Seite 172-176 (DE-627)1761094386 26363402 nnns volume:4 year:2021 number:2 pages:172-176 https://dx.doi.org/10.21608/svuijm.2020.47814.1018 kostenfrei https://doaj.org/article/26388b06d23f4792a6393dbf70d5ba4f kostenfrei https://svuijm.journals.ekb.eg/article_122698.html kostenfrei https://doaj.org/toc/2735-427X Journal toc kostenfrei https://doaj.org/toc/2636-3402 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2021 2 172-176
allfieldsSound	(DE-627)DOAJ048933864 (DE-599)DOAJ26388b06d23f4792a6393dbf70d5ba4f DE-627 ger DE-627 rakwb eng Nagwa Abd El-Sadek Ahmed* verfasserin aut Emerging role of the immunotherapy in treatment of breast cancer 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Breast cancer is a life-threatening malignant tumor that ranks the most frequent cancerin females worldwide. Emerging studies suggest the important role of the immunotherapy in breast cancer.Triple negative breast cancer (TNBC) is associated with the worst prognosis and is resistantto the conventional therapeutic agents. Recently, the immunotherapy has achieved satisfactory results in the treatment of breast cancer in general and in TNBC in particular. The immune checkpoints are targeted in many clinical trials. The checkpoint inhibitors results in advances in treatment of breast cancer, especially refractory molecular subtypes. This review is aimedto highlight the current knowledge on the immunotherapy and the advances in its implications in treatment of breast cancer with emphasis on newly approved therapeutic approaches in this field. Conclusion: The immunotherapy is considered as an emerging therapeutic strategy for treatment of breast cancer, particularly TNBC.Several clinical trials focusing on the potential role of immunotherapy in breast cancer are still under research. tnbc; immunotherapy; programmed death 1; programmed death ligand 1 Medicine R Maisa Hashem Mohammed verfasserin aut In SVU - International Journal of Medical Sciences South Valley University, Faculty of Medicine, 2021 4(2021), 2, Seite 172-176 (DE-627)1761094386 26363402 nnns volume:4 year:2021 number:2 pages:172-176 https://dx.doi.org/10.21608/svuijm.2020.47814.1018 kostenfrei https://doaj.org/article/26388b06d23f4792a6393dbf70d5ba4f kostenfrei https://svuijm.journals.ekb.eg/article_122698.html kostenfrei https://doaj.org/toc/2735-427X Journal toc kostenfrei https://doaj.org/toc/2636-3402 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2021 2 172-176
language	English
source	In SVU - International Journal of Medical Sciences 4(2021), 2, Seite 172-176 volume:4 year:2021 number:2 pages:172-176
sourceStr	In SVU - International Journal of Medical Sciences 4(2021), 2, Seite 172-176 volume:4 year:2021 number:2 pages:172-176
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	tnbc; immunotherapy; programmed death 1; programmed death ligand 1 Medicine R
isfreeaccess_bool	true
container_title	SVU - International Journal of Medical Sciences
authorswithroles_txt_mv	Nagwa Abd El-Sadek Ahmed* @@aut@@ Maisa Hashem Mohammed @@aut@@
publishDateDaySort_date	2021-01-01T00:00:00Z
hierarchy_top_id	1761094386
id	DOAJ048933864
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ048933864</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502074105.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ048933864</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ26388b06d23f4792a6393dbf70d5ba4f</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Nagwa Abd El-Sadek Ahmed*</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Emerging role of the immunotherapy in treatment of breast cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Breast cancer is a life-threatening malignant tumor that ranks the most frequent cancerin females worldwide. Emerging studies suggest the important role of the immunotherapy in breast cancer.Triple negative breast cancer (TNBC) is associated with the worst prognosis and is resistantto the conventional therapeutic agents. Recently, the immunotherapy has achieved satisfactory results in the treatment of breast cancer in general and in TNBC in particular. The immune checkpoints are targeted in many clinical trials. The checkpoint inhibitors results in advances in treatment of breast cancer, especially refractory molecular subtypes. This review is aimedto highlight the current knowledge on the immunotherapy and the advances in its implications in treatment of breast cancer with emphasis on newly approved therapeutic approaches in this field. Conclusion: The immunotherapy is considered as an emerging therapeutic strategy for treatment of breast cancer, particularly TNBC.Several clinical trials focusing on the potential role of immunotherapy in breast cancer are still under research.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">tnbc; immunotherapy; programmed death 1; programmed death ligand 1</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maisa Hashem Mohammed</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">SVU - International Journal of Medical Sciences</subfield><subfield code="d">South Valley University, Faculty of Medicine, 2021</subfield><subfield code="g">4(2021), 2, Seite 172-176</subfield><subfield code="w">(DE-627)1761094386</subfield><subfield code="x">26363402</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:172-176</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.21608/svuijm.2020.47814.1018</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/26388b06d23f4792a6393dbf70d5ba4f</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://svuijm.journals.ekb.eg/article_122698.html</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2735-427X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2636-3402</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2021</subfield><subfield code="e">2</subfield><subfield code="h">172-176</subfield></datafield></record></collection>
author	Nagwa Abd El-Sadek Ahmed*
spellingShingle	Nagwa Abd El-Sadek Ahmed* misc tnbc; immunotherapy; programmed death 1; programmed death ligand 1 misc Medicine misc R Emerging role of the immunotherapy in treatment of breast cancer
authorStr	Nagwa Abd El-Sadek Ahmed*
ppnlink_with_tag_str_mv	@@773@@(DE-627)1761094386
format	electronic Article
delete_txt_mv	keep
author_role	aut aut
collection	DOAJ
remote_str	true
illustrated	Not Illustrated
issn	26363402
topic_title	Emerging role of the immunotherapy in treatment of breast cancer tnbc; immunotherapy; programmed death 1; programmed death ligand 1
topic	misc tnbc; immunotherapy; programmed death 1; programmed death ligand 1 misc Medicine misc R
topic_unstemmed	misc tnbc; immunotherapy; programmed death 1; programmed death ligand 1 misc Medicine misc R
topic_browse	misc tnbc; immunotherapy; programmed death 1; programmed death ligand 1 misc Medicine misc R
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	SVU - International Journal of Medical Sciences
hierarchy_parent_id	1761094386
hierarchy_top_title	SVU - International Journal of Medical Sciences
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1761094386
title	Emerging role of the immunotherapy in treatment of breast cancer
ctrlnum	(DE-627)DOAJ048933864 (DE-599)DOAJ26388b06d23f4792a6393dbf70d5ba4f
title_full	Emerging role of the immunotherapy in treatment of breast cancer
author_sort	Nagwa Abd El-Sadek Ahmed*
journal	SVU - International Journal of Medical Sciences
journalStr	SVU - International Journal of Medical Sciences
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2021
contenttype_str_mv	txt
container_start_page	172
author_browse	Nagwa Abd El-Sadek Ahmed* Maisa Hashem Mohammed
container_volume	4
format_se	Elektronische Aufsätze
author-letter	Nagwa Abd El-Sadek Ahmed*
author2-role	verfasserin
title_sort	emerging role of the immunotherapy in treatment of breast cancer
title_auth	Emerging role of the immunotherapy in treatment of breast cancer
abstract	Background: Breast cancer is a life-threatening malignant tumor that ranks the most frequent cancerin females worldwide. Emerging studies suggest the important role of the immunotherapy in breast cancer.Triple negative breast cancer (TNBC) is associated with the worst prognosis and is resistantto the conventional therapeutic agents. Recently, the immunotherapy has achieved satisfactory results in the treatment of breast cancer in general and in TNBC in particular. The immune checkpoints are targeted in many clinical trials. The checkpoint inhibitors results in advances in treatment of breast cancer, especially refractory molecular subtypes. This review is aimedto highlight the current knowledge on the immunotherapy and the advances in its implications in treatment of breast cancer with emphasis on newly approved therapeutic approaches in this field. Conclusion: The immunotherapy is considered as an emerging therapeutic strategy for treatment of breast cancer, particularly TNBC.Several clinical trials focusing on the potential role of immunotherapy in breast cancer are still under research.
abstractGer	Background: Breast cancer is a life-threatening malignant tumor that ranks the most frequent cancerin females worldwide. Emerging studies suggest the important role of the immunotherapy in breast cancer.Triple negative breast cancer (TNBC) is associated with the worst prognosis and is resistantto the conventional therapeutic agents. Recently, the immunotherapy has achieved satisfactory results in the treatment of breast cancer in general and in TNBC in particular. The immune checkpoints are targeted in many clinical trials. The checkpoint inhibitors results in advances in treatment of breast cancer, especially refractory molecular subtypes. This review is aimedto highlight the current knowledge on the immunotherapy and the advances in its implications in treatment of breast cancer with emphasis on newly approved therapeutic approaches in this field. Conclusion: The immunotherapy is considered as an emerging therapeutic strategy for treatment of breast cancer, particularly TNBC.Several clinical trials focusing on the potential role of immunotherapy in breast cancer are still under research.
abstract_unstemmed	Background: Breast cancer is a life-threatening malignant tumor that ranks the most frequent cancerin females worldwide. Emerging studies suggest the important role of the immunotherapy in breast cancer.Triple negative breast cancer (TNBC) is associated with the worst prognosis and is resistantto the conventional therapeutic agents. Recently, the immunotherapy has achieved satisfactory results in the treatment of breast cancer in general and in TNBC in particular. The immune checkpoints are targeted in many clinical trials. The checkpoint inhibitors results in advances in treatment of breast cancer, especially refractory molecular subtypes. This review is aimedto highlight the current knowledge on the immunotherapy and the advances in its implications in treatment of breast cancer with emphasis on newly approved therapeutic approaches in this field. Conclusion: The immunotherapy is considered as an emerging therapeutic strategy for treatment of breast cancer, particularly TNBC.Several clinical trials focusing on the potential role of immunotherapy in breast cancer are still under research.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	2
title_short	Emerging role of the immunotherapy in treatment of breast cancer
url	https://dx.doi.org/10.21608/svuijm.2020.47814.1018 https://doaj.org/article/26388b06d23f4792a6393dbf70d5ba4f https://svuijm.journals.ekb.eg/article_122698.html https://doaj.org/toc/2735-427X https://doaj.org/toc/2636-3402
remote_bool	true
author2	Maisa Hashem Mohammed
author2Str	Maisa Hashem Mohammed
ppnlink	1761094386
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
up_date	2024-07-03T20:28:44.651Z
_version_	1803591116026544128
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ048933864</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502074105.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ048933864</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ26388b06d23f4792a6393dbf70d5ba4f</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Nagwa Abd El-Sadek Ahmed*</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Emerging role of the immunotherapy in treatment of breast cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Breast cancer is a life-threatening malignant tumor that ranks the most frequent cancerin females worldwide. Emerging studies suggest the important role of the immunotherapy in breast cancer.Triple negative breast cancer (TNBC) is associated with the worst prognosis and is resistantto the conventional therapeutic agents. Recently, the immunotherapy has achieved satisfactory results in the treatment of breast cancer in general and in TNBC in particular. The immune checkpoints are targeted in many clinical trials. The checkpoint inhibitors results in advances in treatment of breast cancer, especially refractory molecular subtypes. This review is aimedto highlight the current knowledge on the immunotherapy and the advances in its implications in treatment of breast cancer with emphasis on newly approved therapeutic approaches in this field. Conclusion: The immunotherapy is considered as an emerging therapeutic strategy for treatment of breast cancer, particularly TNBC.Several clinical trials focusing on the potential role of immunotherapy in breast cancer are still under research.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">tnbc; immunotherapy; programmed death 1; programmed death ligand 1</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maisa Hashem Mohammed</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">SVU - International Journal of Medical Sciences</subfield><subfield code="d">South Valley University, Faculty of Medicine, 2021</subfield><subfield code="g">4(2021), 2, Seite 172-176</subfield><subfield code="w">(DE-627)1761094386</subfield><subfield code="x">26363402</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:172-176</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.21608/svuijm.2020.47814.1018</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/26388b06d23f4792a6393dbf70d5ba4f</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://svuijm.journals.ekb.eg/article_122698.html</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2735-427X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2636-3402</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2021</subfield><subfield code="e">2</subfield><subfield code="h">172-176</subfield></datafield></record></collection>
score	7.401332

Nicht das Richtige dabei?

Schreiben Sie uns!

Emerging role of the immunotherapy in treatment of breast cancer

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?